Skip to main content

PARP inhibitors

Research Reports
06/05/2023
Emma L. Barber, MD, and colleagues investigate current and real-world practice patterns for patients receiving maintenance therapy for recurrent ovarian cancer after second-line chemotherapy.
Emma L. Barber, MD, and colleagues investigate current and real-world practice patterns for patients receiving maintenance therapy for recurrent ovarian cancer after second-line chemotherapy.
Emma L. Barber, MD, and...
06/05/2023
Journal of Clinical Pathways
Overview of the Updated NCCN Guidelines on Ovarian Cancer
Special Report
06/17/2020
While ovarian cancer is the second most common gynecologic cancer in the United States, behind uterine cancer,1 it is the top gynecologic cancer in mortality.2 In 2020, an estimated 21,750 new cases of ovarian cancer...
While ovarian cancer is the second most common gynecologic cancer in the United States, behind uterine cancer,1 it is the top gynecologic cancer in mortality.2 In 2020, an estimated 21,750 new cases of ovarian cancer...
While...
06/17/2020
Journal of Clinical Pathways
News
06/09/2020
Olaparib improves survival outcomes for patients with germline BRCA-mutated, platinum-sensitive, relapsed ovarian cancer who received at least two prior lines of platinum-based chemotherapy, according to a...
Olaparib improves survival outcomes for patients with germline BRCA-mutated, platinum-sensitive, relapsed ovarian cancer who received at least two prior lines of platinum-based chemotherapy, according to a...
...
06/09/2020
Journal of Clinical Pathways
Ovarian Cancer Maintenance: PRIMA, PAOLA-1, VELIA, and Others
ENGAGING EXPERTS
06/05/2020
Michael Birrer, MD, PhD, director of the Winthrop P Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, discusses the latest PARP inhibitor indications for frontline maintenance in ovarian cancer, as well as the...
Michael Birrer, MD, PhD, director of the Winthrop P Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, discusses the latest PARP inhibitor indications for frontline maintenance in ovarian cancer, as well as the...
Michael Birrer, MD, PhD,...
06/05/2020
Journal of Clinical Pathways
News
06/03/2020
HRD test results used in published and ongoing clinical trials for PARP inhibitor-treatment of ovarian cancer are not equivalent, according to the results of a study presented at the American Society of Clinical...
HRD test results used in published and ongoing clinical trials for PARP inhibitor-treatment of ovarian cancer are not equivalent, according to the results of a study presented at the American Society of Clinical...
HRD...
06/03/2020
Journal of Clinical Pathways